Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Biohackers are stacking them in elaborate protocols
The peptide was investigated by Australian pharmaceutical company Lateral Pharma as a potential management of migraines and neuropathic pain, but the results were similar to placebo [10, 11]
Unlike hGH, which carries broader systemic effects and risks associated with elevated IGF-1 levels, AOD9604 appears to selectively promote fat metabolism without triggering growth-related side effects, suggesting its potential as a safer therapeutic candidate for obesity and metabolic disorders [2]
Digest Dis Sci 37(4):583588 Hsieh MJ, Liu HT, Wang CN et al (2017) Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Speak with a licensed clinician before starting any peptide protocol, and review the regulatory status section before assuming legal availability
